Last reviewed · How we verify
Hydrochlorthiazide and Amiloride
Hydrochlorthiazide and Amiloride is a Small molecule drug developed by University of Cambridge. It is currently FDA-approved.
Hydrochlorthiazide and Amiloride, marketed by the University of Cambridge, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its market position. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Hydrochlorthiazide and Amiloride |
|---|---|
| Sponsor | University of Cambridge |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes (EARLY_PHASE1)
- Comparison of Single and Combination Diuretics in Low-Renin Hypertension (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrochlorthiazide and Amiloride CI brief — competitive landscape report
- Hydrochlorthiazide and Amiloride updates RSS · CI watch RSS
- University of Cambridge portfolio CI